Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, at 8:45 AM EDT on Thursday, June 4, 2026. Read more…
Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today are proud to announce that Renée Aguiar-Lucander, CEO, Hansa Biopharma has been named one of Sweden’s Most Influential Business Women of 2026 by Dagens industri. This nomination recognizes leaders with significant influence over the development, competitiveness and future of Swedish business. The […]
Lund, Sweden, 18 May. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled “Scaling Success: Key Drivers for Growing Nordic Biotechs” at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026. Read more…
Experienced MedTech leader to guide Amber Implants’ transition from development into commercialization following FDA clearance of the VCFix® Spinal System Company preparing for U.S. market launch in 2026 THE HAGUE, The Netherlands, Nov. 6, 2025 /PRNewswire/ — Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announced the appointment of Vincent Gardès as Chief Executive […]
Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech developing an oral therapy for frontotemporal dementia, today announces the appointment of Jacob Falck Hansen as Chief Executive Officer (CEO). Jacob Falck Hansen brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He […]
